Shares of Merck KGaA (FRA:MRK) have been given an average rating of “Hold” by the twenty-one research firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and five have assigned a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is €101.00 ($117.44).
Several research analysts have recently issued reports on MRK shares. JPMorgan Chase & Co. set a €100.00 ($116.28) target price on shares of Merck KGaA and gave the stock a “neutral” rating in a research note on Wednesday, January 2nd. Sanford C. Bernstein set a €105.00 ($122.09) target price on shares of Merck KGaA and gave the stock a “buy” rating in a research note on Thursday, January 3rd. Barclays set a €78.00 ($90.70) target price on shares of Merck KGaA and gave the stock a “sell” rating in a research note on Tuesday, January 15th. Nord/LB set a €80.00 ($93.02) target price on shares of Merck KGaA and gave the stock a “sell” rating in a research note on Thursday, January 24th. Finally, Kepler Capital Markets set a €108.00 ($125.58) price objective on shares of Merck KGaA and gave the company a “buy” rating in a report on Thursday, January 24th.
Shares of FRA MRK opened at €97.18 ($113.00) on Monday. Merck KGaA has a 52-week low of €76.60 ($89.07) and a 52-week high of €115.00 ($133.72).
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, and colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Featured Story: How to calculate compound interest
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.